QuantHealth has raised $45.0M in a Series B round, a fresh infusion of capital for a company that has quietly become a heavyweight in the business of de-risking clinical trials. The funding arrives as the AI-driven drug development sector draws sharper investor attention, though the backers behind this particular round were not disclosed.
The company鈥檚 pitch is straightforward: it has simulated more than 600 trials across 30 indications, claiming up to 90% accuracy in predicting outcomes. That track record has already won over 12 of the world鈥檚 top 20 pharma firms, which use QuantHealth鈥檚 AI-native platform to test thousands of trial design variations before committing real patients and real dollars. The new capital is aimed at scaling that operation, though specifics on deployment remain under wraps.
















